We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Biopharma Credit Plc | LSE:BPCP | London | Ordinary Share | GB00BDGKMY29 | ORD USD0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 70.80 | 68.60 | 73.00 | 2,374 | 08:08:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 135.74M | 108.45M | 0.0833 | 8.50 | 922.3M |
TIDMBPCR
RNS Number : 4903A
BioPharma Credit PLC
22 January 2024
BIOPHARMA CREDIT PLC
Notification of Transactions by
Persons Discharging Managerial Responsibilities and
Persons Closely Associated with them
1. Details of person discharging managerial responsibilities/person closely associated with them a) Name Anita Hyman ------------------------ -------------------------------------------- 2. Reason for the notification ---------------------------------------------------------------------- a) Position / status Person Closely Associated with Harry Hyman (Director of BioPharma Credit PLC) ------------------------ -------------------------------------------- b) Initial notification Initial notification / amendment ------------------------ -------------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ---------------------------------------------------------------------- a) Name BioPharma Credit PLC ------------------------ -------------------------------------------- b) LEI 213800AV55PYXAS7SY24 ------------------------ -------------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ---------------------------------------------------------------------- a) Description Ordinary Shares of $0.01 each of the financial instrument GB00BDGKMY29 Identification Code -------------------------- ------------------------------------------ b) Nature of the Purchase of Shares (acquired as part transaction of dividend reinvestment) -------------------------- ------------------------------------------ c) Price(s) and Price(s) Volume(s) volume(s) GBP0.724706 126 ---------- -------------------------- ------------------------------------------ d) Aggregated information - Aggregated volume N/A - Price -------------------------- ------------------------------------------ e) Date of the 05.01.24 transaction -------------------------- ------------------------------------------ f) Place of the London Stock Exchange (XLON) transaction -------------------------- ------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBDGDBSXDDGSD
(END) Dow Jones Newswires
January 22, 2024 07:35 ET (12:35 GMT)
1 Year Biopharma Credit Chart |
1 Month Biopharma Credit Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions